BioNTech SE ((BNTX)) provided an update.
BioNTech SE has settled a dispute with the National Institutes of Health (NIH) over royalties allegedly owed on sales of its COVID-19 vaccine, co-developed with Pfizer. The settlement includes a $791.5 million payment to the NIH, resolving previous claims and adjusting future royalty arrangements. The settlement does not imply an admission of liability by BioNTech, and Pfizer has agreed to repay $364.5 million of the settlement amount.
More about BioNTech SE
BioNTech SE is a biotechnology company based in Mainz, Germany, best known for its development of mRNA-based vaccines and immunotherapies. The company is a major player in the pharmaceutical industry, best known for its collaboration with Pfizer in the production of the COVID-19 vaccine.
YTD Price Performance: 7.80%
Average trading volume: 820,259
Technical sentiment consensus rating: To sell
Current market capitalization: $27.28 billion
View more data on BNTX stock at TipRanks’ Stock Analysis Page.
